The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Somnath Chatterjee
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts more than Nifty Microcap 250 and 4.7 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Somnath Chatterjee, Promoter, Chairman & Joint Managing Director of Suraksha Diagnostic Ltd, has purchased 8,200 equity shares (0.016% of the company's equity) through an open market purchase on 14 August 2025. His total holding has risen from 26,38,768 shares (5.067%) to 26,46,968 shares (5.082%) of the company's paid-up equity capital of 5,20,80,758 shares. The acquisition was made in his personal capacity as a promoter and disclosed to BSE and NSE under Regulation 29(2) of the SEBI Takeover Regulations. No encumbrance (pledge/lien) is involved in this transaction.
This is a small open-market purchase by the promoter, indicating confidence in the company. The increase in promoter holding is marginal (0.016%), so this is likely a routine personal investment move rather than a strategic stake change.